Structured Abstract
Background Rates of severe illness and mortality from SARS-CoV-2 are greater for males, but the mechanisms for this difference are unclear. Understanding the differences in outcomes between males and females across the age spectrum will guide both public health and biomedical interventions.
Methods Retrospective cohort analysis of SARS-CoV-2 testing and admission data in a health system. Patient-level data were assessed with descriptive statistics and logistic regression modeling was used to identify features associated with increased male risk of severe outcomes.
Results In 213,175 SARS-CoV-2 tests, despite similar positivity rates (8.2%F vs 8.9%M), males were more frequently hospitalized (28%F vs 33%M). Of 2,626 hospitalized individuals, females had less severe presenting respiratory parameters and males had more fever. Comorbidity burden was similar, but with differences in specific conditions. Medications relevant for SARS-CoV-2 were used at similar frequency except tocilizumab (M>F). Males had higher inflammatory lab values. In a logistic regression model, male sex was associated with a higher risk of severe outcomes at 24 hours (odds ratio (OR) 3.01, 95%CI 1.75, 5.18) and at peak status (OR 2.58, 95%CI 1.78,3.74) among 18-49 year-olds. Block-wise addition of potential explanatory variables demonstrated that only the inflammatory labs substantially modified the OR associated with male sex across all ages.
Conclusion Higher levels of clinical inflammatory labs are the only features that are associated with the heightened risk of severe outcomes and death for males in COVID-19.
Trial registration NA
Funding Hopkins inHealth; COVID-19 Administrative Supplement (HHS Region 3 Treatment Center), Office of the ASPR; NIH/NCI U54CA260492 (SK), NIH/NIA U54AG062333 (SK).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
The data utilized were part of JH-CROWN: The COVID PMAP Registry, which is based on the contribution of many patients and clinicians and is funded by Hopkins inHealth, the Johns Hopkins Precision Medicine Program. Drs. Garibaldi, Muschelli, Robinson, Bandeen-Roche, and Gupta and Mr. Schumock received funding from the COVID-19 Administrative Supplement for the HHS Region 3 Treatment Center from the Office of the Assistant Secretary for Preparedness and Response. Drs S. Klein, Zeger and Mr. Betz received funding from the NIH/NCI funded COVID-19 Serology Center of Excellence (U54CA260492). Dr. Scully is supported by R01AI154541 (NIAID/ORWH). The funders had no role in the design, analysis, or conduct of the study or in the decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by IRB00250975 at all of the participating hospitals in the Johns Hopkins Health System: Howard County General Hospital, Johns Hopkins Bayview Medical Center, Suburban Hospital, Johns Hopkins Hospital, and Sibley Memorial Hospital. It was deemed by the IRB to be minimal risk and a waiver of informed consent was granted. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data for this study is maintained in the Johns Hopkins Precision Medicine Analytics Platform (PMAP).
